

- Siegal R, Naishadham D, Jemal A. Cancer statistics 2013. *CA Cancer J Clin* 2013;63:11–30.
- Maralani S, Wood DP Jr, Grignon D, et al. Incidence of urethral involvement in female bladder cancer: an anatomic pathologic study. *Urology* 1997;50:537–541.
- Erckert M, Stenzl A, Falk M, et al. Incidence of urethral tumor involvement in 910 men with bladder cancer. *World J Urol* 1996;14:3–8.
- Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. *J Urol* 2000;164:1523–1525.
- Oldbring J, Glifbert I, Mikulowski P, et al. Carcinoma of the renal pelvis and ureter following bladder carcinoma: frequency, risk factors and clinicopathological findings. *J Urol* 1989;141:1311–1313.
- Rabbani F, Perrotti M, Russo P, et al. Upper-tract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillance. *J Clin Oncol* 2001;19:94–100.
- Hurle R, Losa A, Manzetti A, et al. Upper urinary tract tumors developing after treatment of superficial bladder cancer: 7-year follow-up of 591 consecutive patients. *Urology* 1999;53:1144–1148.
- Toncheval DI, Antanosova SY, Gergov TD, et al. Genetic changes in uroepithelial tumors of patients with Balkan endemic nephropathy. *J Nephrol* 2002;15:387–393.
- Nortier JL, Martínez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (*Aristolochia fangchi*). *N Engl J Med* 2000;342:1686–1692.
- Grollman AP, Shibutani S, Moriya M, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. *Proc Natl Acad Sci U S A* 2007;104:12129–12134.
- Jelaković B, Karanović S, Vuković-Lela I, et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. *Kidney Int* 2012;81:559–567.
- Hranjec T, Kovac A, Kos J, et al. Endemic nephropathy: the case for chronic poisoning by Aristolochia. *Croat Med J* 2005;46:116–125.
- Yang MH, Chen KK, Yan CC, et al. Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan. *Urology* 2002;59:681–687.
- Chen CH, Dickman KG, Moriya M, et al. Aristolochic acid-associated urothelial cancer in Taiwan. *Proc Natl Acad Sci U S A* 2012;109:8241–8246.
- Lai MN, Wang SM, Chen PC, et al. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. *J Natl Cancer Inst* 2010;102:179–186.
- Soloman DA, Kim JS, Bondaruk J, et al. Frequent truncating mutations of STAG2 in bladder cancer. *Nat Genet* 2013;45:1428–1430.
- Guo G, Sun X, Chen C, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. *Nat Genet* 2013;45:1459–1463.
- Balbas-Martinez C, Sagraera A, Carrillo-de-Santa-Pau E, et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. *Nat Genet* 2013;45:1464–1469.
- Shinohara N, Koyanagi T. Ras signal transduction in carcinogenesis and progression of bladder cancer: molecular target for treatment? *Urol Res* 2002;30:273–278.
- Primdahl H, von der Masse H, Sorenson FB, et al. Immunohistochemical study of the expression of cell cycle regulating proteins at different stages of bladder cancer. *J Cancer Res Clin Oncol* 2002;128:295–301.
- Olesen SH, Thykjaer T, Orntoft TN. Mitotic checkpoint genes hBuB1, hBuB1B, hBuB3 and TTK in human bladder cancer, screening of mutations and loss of heterozygosity. *Carcinogenesis* 2001;22:813–815.
- Feldman AS, Tang Z, Kirley S, et al. Expression of CABLES, a cell cycle regulatory gene is lost in invasive transitional cell carcinoma of the bladder. *J Urol* 2003;169:188.
- Sgambato A, Migaldi M, Faraglia B, et al. Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome. *Int J Cancer* 2002;97:671–678.
- Santos LL, Amaro T, Pereira SA, et al. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder. *Eur J Surg Oncol* 2003;29:74–80.
- Bianco FJ Jr, Cervasi DC, Tiguert R, et al. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. *Clin Cancer Res* 1998;4:3011–3016.
- Zeegers MP, Goldbohm RA, van den Brandt PA. A prospective study on active and environmental tobacco smoking and bladder cancer risk (The Netherlands). *Cancer Causes Control* 2002;13:83–90.
- Moyer VA. Screening for bladder cancer: US Preventive Services Task Force recommendation statement. *Ann Intern Med* 2011;153:246–251.
- Mohr DN, Offord KP, Owen RA, et al. Asymptomatic microhematuria and urologic disease: a population-based study. *JAMA* 1986;256:224–229.
- Mishriki SF, Nabi G, Cohen NP, et al. Diagnosis of urologic malignancies in patients with asymptomatic dipstick hematuria: prospective study with 13 years' follow-up. *Urology* 2008;71:13–16.
- Messing EM, Madeb R, Young T, et al. Long-term outcome of hematuria home screening for bladder cancer in men. *Cancer* 2006;107:2173–2179.
- Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. *J Urol* 1998;159:394–398.
- Oeda T, Manabe D. The usefulness of urinary FDP in the diagnosis of bladder cancer: comparison with NMP22, BTA and cytology. *Nippon Hinyokika Gakkai Zasshi* 2001;92:1–5.
- Eissa S, Swellam M, Sadek M, et al. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. *J Urol* 2002;168:465–469.
- Ichikawa T, Nakayama Y, Yamada D, et al. Clinical evaluation of basic fetoprotein in bladder cancer. *Nippon Hinyokika Gakkai Zasshi* 2000;91:579–583.
- Strefford JC, Lillington DM, Steggall M, et al. Novel chromosome findings in bladder cancer cell lines detected with multiplex fluorescence in situ hybridization. *Cancer Genet Cytogenet* 2002;135:139–146.
- Utting M, Werner W, Dahse R, et al. Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer. *Clin Cancer Res* 2002;8:35–40.
- Ito H, Kyo S, Kanaya T, et al. Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer. *Clin Cancer Res* 1998;4:2807–2810.
- Boman H, Hedelin H, Holmang S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. *J Urol* 2002;167:80–83.
- Lokeshwar VB, Habuchi T, Grossman HB, et al. Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers. *Urology* 2005;66:35–63.
- Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analysis. *Urology* 2003;61:109–118.
- Young RH. Pathology of carcinomas of the urinary bladder. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, eds. *Comprehensive Textbook of Genital Urinary Oncology*, 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000:310.
- Reuter VE. Pathology of bladder cancer: assessment of prognostic variables in response to therapy. *Semin Oncol* 1990;17:524–532.
- Epstein JI, Amin MB, Reuter VE, et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. *Am J Surg Pathol* 1998;22:1435–1448.
- Fairey AS, Daneshmand S, Wang L, et al. Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy. *Urol Oncol* 2014;32:110–116.
- Willis DL, Porten SP, Kamat AM. Should histologic variants alter definitive treatment of bladder cancer? *Curr Opin Urol* 2013;23:435–443.
- Wang J, Wang FW, Lagrange CA, et al. Clinical features of sarcomatoid carcinoma (carcinosarcoma) of the urinary bladder: analysis of 221 cases. *Sarcoma* 2010; 2010:pii: 454792.
- Young RH, Oliva E. Transitional cell carcinomas of the urinary bladder that may be underdiagnosed: a report of four invasive cases exemplifying the homology between neoplastic and nonneoplastic transitional cell lesions. *Am J Surg Pathol* 1996;20:1448.
- Younes M, Sussman J, True LD. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. *Cancer* 1990;66:543–548.
- Farrow GM. Pathology of carcinoma in situ of the urinary bladder and related lesions. *J Cell Biochem* 1992;161:39–43.
- Melamed MR, Reuter VE. Pathology and staging of urothelial tumors of the kidney and ureter. *Urol Clin North Am* 1993;20:333–347.
- Sidransky D, Frost P, Von Eschenbach A, et al. The clonal origin of bladder cancer. *N Engl J Med* 1992;326:737–740.
- Miyao N, Tsai YC, Lerner SP, et al. Role of chromosome IX in human bladder cancer. *Cancer Res* 1993;53:4066–4070.
- Williams SG, Buscarini M, Stein JP. Molecular markers for diagnosis, staging and prognosis of bladder cancer. *Oncology* 2001;15:1461–1470.
- Markl IDC, Salem CE, Jones PA. Molecular biology of bladder cancer. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, eds. *The Comprehensive Textbook of Genitourinary Oncology*, 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000:298.
- Raghavan D. Molecular targeting and pharmacogenomics in the management of advanced bladder cancer. *Cancer* 2003;97:2086–2089.
- Cordon-Cardo C. Molecular alterations associated with bladder cancer initiation and progression. *Scand J Urol Nephrol Suppl* 2008;218:154–165.
- Stadler WM, Lerner SP, Groshen S, et al. S Phase II study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. *J Clin Oncol* 2011;29:3443–3449.
- Colquhoun CL, Jones GDD, Al-Moneef M, et al. Improving and predicting radiosensitivity in muscle invasive bladder cancer. *J Urol* 2003;169:1983–1992.
- Cote RJ, Esrig D, Groshen S, et al. p53 and the treatment of bladder cancer. *Nature* 1997;385:123–125.
- Sarkis A, Bajorin D, Reuter V, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. *J Clin Oncol* 1995;13:1384–1390.
- Rodel C, Grabenbauer GG, Rodel F, et al. Apoptosis, p53, bcl-2, Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. *Int J Radiat Oncol Biol Phys* 2000;46:1213.

62. Smith ND, Rubinstein JN, Eggner SE, et al. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. *J Urol* 2003;169:1219–1228.
63. Al-Sukhun S, Hussain M. Current understanding of the biology of advanced bladder cancer. *Cancer* 2003;97:2064–2075.
64. Neal DE, Sharples L, Smith K, et al. The epidermal growth factor receptor and the prognosis of bladder cancer. *Cancer* 1990;65:1619–1625.
65. Wood DP Jr, Fair WR, Chaganti RS. Evaluation of epidermal growth factor receptor DNA amplification and mRNA expression in bladder cancer. *J Urol* 1992;147:274–277.
66. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. *Br J Cancer* 1994;69:1120–1125.
67. Mellon JK, Lunec J, Wright C, et al. C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. *J Urol* 1996;155:321–326.
68. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. *Clin Cancer Res* 2000;6:2053–2063.
69. Jimenez RE, Hussain M, Bianco FJ Jr, et al. Her-2/neu over-expression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. *Clin Cancer Res* 2001;7:2440–2447.
70. Chakravarti A, Winter K, Wu CL, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invasive bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. *Int J Radiat Oncol Biol Phys* 2005;62:309–317.
71. Lautenschlaeger T, George A, Klimowicz AC, et al. Bladder preservation therapy for muscle-invasive bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival. *Oncologist* 2013;18:685–686.
72. Sabichi AL, Lee JJ, Grossman HB, et al. A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. *Cancer Prev Res (Phila)* 2011;4:1580–1589.
73. Choudhury A, Nelson LD, Teo MT, et al. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. *Cancer Res* 2010;70:7017–7026.
74. Laurberg JR, Brems-Eskildsen AS, Nordentoft I, et al. Expression of TIIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. *BJU Int* 2012;110:E1228–E1236.
75. Danilchenko DI, Riedl CR, Sachs MD, et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. *J Urol* 2005;174:2129–2133.
76. Denzinger S, Burger M, Walter B, et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. *Urology* 2007;69:675–679.
77. Naselli A, Introini C, Timossi L, et al. A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. *Eur Urol* 2012;61:908–913.
78. Stenzl A, Penkoff H, Dajc-Sommerer E, et al. Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: A multicenter randomized, double-blind, placebo-controlled trial. *Cancer* 2011;117:938–947.
79. American Joint Committee on Cancer. *Cancer Staging Manual*, 7th ed. New York: Springer-Verlag; 2008.
80. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. *N Engl J Med* 2003;348:2491–2499.
81. Di Stasi SM, Valenti M, Verri C, et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. *Lancet Oncol* 2011;12:891–899.
82. Lamm DL, Blumenstein BA, Crisman JD, et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. *J Urol* 2000;163:1124–1129.
83. Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. *Eur Urol* 2013;63:462–472.
84. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. *J Urol* 2003;169:900.
85. Shang PF, Kwong J, Wang ZP, et al. Intravesical BCG vs epirubicin for Ta and T1 bladder cancer. *Cochrane Database Syst Rev* 2011;(5):CD006885.
86. Nieder AM, Brausi M, Lamm D, et al. Management of stage T1 tumors of the bladder: International Consensus Panel. *Urology* 2005;66:108–125.
87. O'Donnell MA, Krohn J, DeWolf WC, et al. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guérin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guérin alone previously failed. *J Urol* 2001;166:1300–1304.
88. Rosevear HM, Lightfoot AJ, Birusingh KK, et al. Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ. *J Urol* 2011;186:817–823.
89. Steinberg G, Bahnson R, Brosnan S, et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. *J Urol* 2000;163:761–767.
90. Addeo R, Caraglia M, Bellini S, et al. Randomized phase III trial on gemcitabine versus mitomycin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. *J Clin Oncol* 2010;28:543–548.
91. Skinner EC, Goldman B, Sakr WA, et al. 1666 SWOG S0353 phase II trial of intravesical gemcitabine in patients with non-muscle invasive bladder cancer who recurred following at least two prior courses of BCG. *J Urol* 2012;187:e673.
92. Laudano MA, Barlow LJ, Murphy AM, et al. Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. *Urology* 2010;75:134–137.
93. Shahin O, Thalmann GN, Rentsch C, et al. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guérin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. *J Urol* 2003;169:96–100.
94. Davis JW, Sheth SI, Doviak MJ, et al. Superficial bladder carcinoma treated with bacillus Calmette-Guérin: progression-free and disease specific survival with minimum 10-year followup. *J Urol* 2002;167:494–500.
95. You R, Patard JJ, Benhard H, et al. Outcome of radical cystectomy for bladder cancer according to the disease type at presentation. *BJU Int* 2002;89:374–378.
96. Gray PJ, Shipley WU, Efstathiou JA, et al. Recent advances and the emerging role for chemoradiation in nonmuscle invasive bladder cancer. *Curr Opin Urol* 2013;23:429–434.
97. McDougal WS. Urethrectomy. In: McDougal WS, ed. *Rob and Smith's Operative Surgery, Urology*, 4th ed. London: Butterworth; 1983:526.
98. Knoedler JJ, Boorjian SA, Kim SP, et al. Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. *J Urol* 2012;188:1115–1119.
99. Gschwend JE, Dahm P, Fair WR. Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy. *Eur Urol* 2002;41:440–448.
100. Stein JP, Cai J, Groshen S, et al. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. *J Urol* 2003;170:35–41.
101. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. *J Clin Oncol* 2001;19:666–675.
102. Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: a contemporary series. *J Urol* 2001;165:1111–1116.
103. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. *N Engl J Med* 2003;349:859–866.
104. McDougal WS. Metabolic complications of urinary intestinal diversion. *J Urol* 1992;147:1199–1208.
105. Eisenberg M, Thompson R, Frank I, et al. Long-term renal function outcomes after radical cystectomy. *J Urol* 2014;191:1–7.
106. Srinivas S, Mahalati K, Freiha FS. Methotrexate tolerance in patients with ileal conduits and continent diversions. *Cancer* 1998;82:1134–1136.
107. Chahal R, Sundaram SK, Iddenden R, et al. A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire. *Eur Urol* 2003;43:246–257.
108. Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. *Eur Urol* 2009;55:164–174.
109. Eswara JR, Efstathiou JA, Heney NM, et al. Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. *J Urol* 2012;187:463–468.
110. Gakis G, Efstathiou J, Lerner SP, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. *Eur Urol* 2013;63:45–57.
111. Shipley WU, Prout GR Jr, Einstein AB, et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. *JAMA* 1987;258:931–935.
112. Coppin CM, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 1996;14:2901–2907.
113. Shipley WU, Prout GR Jr, Kaufman SD, et al. Invasive bladder carcinoma. The importance of initial transurethral surgery and other significant prognostic factors for improved survival with full-dose irradiation. *Cancer* 1987;60:514–520.

114. Dunst J, Sauer R, Schrott KM, et al. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. *Int J Radiat Oncol Biol Phys* 1994;30:261–266.
115. Tester W, Porter A, Asbell S, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. *Int J Radiat Oncol Biol Phys* 1993;25:783–790.
116. Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. *J Clin Oncol* 1996;14:119–126.
117. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. *J Clin Oncol* 1998;16:3576–3583.
118. Housset M, Dufour B, Durdux C, et al. [Concurrent radio-chemotherapy in infiltrating cancer of the bladder: a new therapeutic approach.] *Cancer Radiother* 1998;2:67s–72s.
119. Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. *J Clin Oncol* 2002;20:3061–3071.
120. Rodel C, Grabenbauer GG, Kuhn R, et al. Organ preservation in patients with invasive bladder cancer: initial results of an intensified protocol of transurethral surgery and radiation therapy plus concurrent cisplatin and 5-fluorouracil. *Int J Radiat Oncol Biol Phys* 2002;52:1303.
121. Rodel C, Grabenbauer GG, Kuhn R, et al. Invasive bladder cancer: organ preservation by radiochemotherapy. *Front Radiat Ther Oncol* 2002;36:118–130.
122. Kaufman DS, Winter KA, Shipley WU, et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing trans-urethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. *Urology* 2009;73:833–837.
123. Shipley WU, Kaufman DS, Tester WJ, et al. Overview of bladder cancer trials in the Radiation Therapy Oncology Group. *Cancer* 2003;97:2115–2119.
124. Mitin T, Hunt D, Shipley WU, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. *Lancet Oncol* 2013;14:863–872.
125. Oh KS, Soto DE, Smith DC, et al. Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. *Int J Radiat Oncol Biol Phys* 2009;74:511–517.
126. Choudhury A, Swindell R, Logue JP, et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. *J Clin Oncol* 2011;29:733–738.
127. Hussain SA, Stocken DD, Peake DR, et al. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. *Br J Cancer* 2004;90:2106–2111.
128. James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. *N Engl J Med* 2012;366:1477–1488.
129. Coen JJ, Paly JJ, Niemierko A, et al. Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer. *Int J Radiat Oncol Biol Phys* 2013;86:311–316.
130. Efstathiou JA, Spiegel DY, Shipley WU, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. *Eur Urol* 2012;61:705–711.
131. Gray PJ, Fedewa SA, Shipley WU, et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. *Eur Urol* 2013;63:823–829.
132. Zietman AL, Grocela J, Zehr E, et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of T<sub>a</sub>, T<sub>1</sub>, and T<sub>is</sub> recurrence within the retained bladder. *Urology* 2001;58:380–385.
133. Horwich A, Dearnaley D, Huddart R, et al. A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. *Radiother Oncol* 2005;75:34–43.
134. Efstathiou JA, Bae K, Shipley WU, et al. Late pelvic toxicity following bladder-sparing therapy in patients with invasive bladder cancer: analysis of RTOG 89-03, 95-06, 97-06, 99-06. *J Clin Oncol* 2009;27:4055–4061.
135. Tumer SL, Swindell R, Bowl N, et al. Bladder movement during radiation therapy for bladder cancer: implications for treatment planning. *Int J Radiat Oncol Biol Phys* 1997;39:355–360.
136. Aluwini S, van Rooij PH, Kirkels WJ, et al. Bladder function preservation with brachytherapy, external beam radiation therapy, and limited surgery in bladder cancer patients: long-term results. *Int J Radiat Oncol Biol Phys* 2014;88:611–617.
137. Wijkstrom H, Norming U, Lagerkvist M, et al. Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patients. *Br J Urol* 1998;81:686–691.
138. Gray PJ, Lin CC, Jemal A, et al. Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the National Cancer Data Base. *Int J Radiat Oncol Biol Phys* 2014;88:1048–1056.
139. Zehnder P, Studer UE, Skinner EC, et al. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. *J Urol* 2011;186:1261–1268.
140. Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. *J Clin Oncol* 2001;19:89–93.
141. Scher H, Shipley W, Herr H. *Cancer of the Bladder*, 5th ed. Philadelphia: JB Lippincott; 1997.
142. Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. *J Clin Oncol* 1993;11:2150–2157.
143. Herr HW. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer. *Eur Assoc Urol* 2008;54:126–132.
144. Black PC, Brown GA, Grossman HB, et al. Neoadjuvant chemotherapy for bladder cancer. *World J Urol* 2006;24:531–542.
145. Vogelzang NJ. Neoadjuvant MVAC: the long and winding road is getting shorter and straighter [editorial]. *J Clin Oncol* 2001;19:4003–4004.
146. Hall RR. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomized controlled trial. *Lancet* 1999;354:533–540.
147. Hall RR. Updated results of a randomized controlled trial of neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle invasive bladder cancer. *Proc Am Soc Clin Oncol* 2002;21:178.
148. International Collaboration of Trialists. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy in muscle-invasive bladder cancer. Long-term results of the BA06 30894 trial. *J Clin Oncol* 2011;29:2171–2177.
149. Sharma P, Bajorin D. Controversies in neoadjuvant and adjuvant chemotherapy for muscle-invasive urothelial cancer and clinical research initiatives in locally advanced disease. *Am Soc Clin Oncol* 2003;1092:478.
150. Malmstrom PU, Rintala E, Wahlqvist R, et al. Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. *J Urol* 1996;155:1903.
151. Sherif A, Rintala E, Mestad O, et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer. Nordic Trial 2. *Scand J Urol Nephrol* 2002;36:419–425.
152. Raghavan D, Quinn D, Skinner DG, et al. Surgery and adjunctive chemotherapy for invasive bladder cancer. *Surg Oncol* 2002;11:55–63.
153. Advanced Bladder Cancer Overview Collaboration. Neoadjuvant chemotherapy for invasive bladder cancer. *Cochrane Database Syst Rev* 2005;2:CD005246.
154. Winquist E, Waldron T, Segal R, et al., eds. *Use of Neoadjuvant Chemotherapy in Transitional Cell Carcinoma of the Bladder*. Practice Guideline Report #3-2-2 (Version 2.2005). Toronto: Cancer Care Ontario; 2012.
155. Winquist E, Waldron T, Segal R, et al. Neoadjuvant chemotherapy in transitional cell carcinoma of the bladder: a systematic review and meta-analysis. *J Urol* 2004;171:561–569.
156. Milowsky MI, Stadler WM, Bajorin DF. Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer. *BJU Int* 2008;102:1339–1344.
157. Dash A, Pettus JA 4th, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. *Cancer* 2008;113:2471–2477.
158. Yafi FA, Kassouf W. Is neoadjuvant chemotherapy with gemcitabine plus cisplatin beneficial in patients with muscle-invasive bladder cancer? *Expert Rev Anticancer Ther* 2009;9:747–752.
159. Sonpavde G, Goldman BH, Speights VO, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. *Cancer* 2008;115:4101.
160. Weight CJ, Garcia JA, Hansel DE, et al. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. *Expert Rev Anticancer Ther* 2009;9:792–799.
161. Dreicer R. Chemotherapy for muscle-invasive bladder cancer in the perioperative setting: current standards. *Urol Oncol* 2007;25:72–75.
162. Donat SM. Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: strategy versus reality. *J Natl Compr Canc Netw* 2009;7:40–47.
163. Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin and cisplatin neo-adjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. *Clin Cancer Res* 2005;11:2625.
164. Prout GR Jr, Griffin PP, Shipley WU. Bladder carcinoma as a systemic disease. *Cancer* 1979;43:2532–2539.
165. Bellmunt J, Guillem V, Paz-Ares L, et al. Phase I–II study of paclitaxel, cisplatin and gemcitabine in advanced transitional-cell carcinoma of the urothelium. *J Clin Oncol* 2000;18:3247–3255.
166. Studer UE, Bacchi M, Biedermann C, et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. *J Urol* 1994;152:81–84.
167. Bono AV, Benvenuti C, Reali L, et al. Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group. *Prog Clin Biol Res* 1989;303:533–540.

168. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. *J Urol* 1996;155:495-499.
169. Skinner DG, Daniels JR, Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. *J Urol* 1991;145:459-464.
170. Stockle M, Meyenburg W, Wellek S, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): Improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy results of a controlled prospective study. *J Urol* 1992;148:302-306.
171. Stockle M, Meyenburg W, Wellek S, et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. *J Urol* 1995;153:47-52.
172. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. *Eur Urol* 2005;48(2):189-199.
173. Cognetti F, Ruggeri EM, Felici A, et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian multicenter phase III trial. *Ann Oncol* 2012;23:695-700.
174. Gallagher DJ, Milowsky MI, Bajorin DF. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. *Cancer* 2008;113:1284-1293.
175. Calabro F, Sternberg CN. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. *Eur Urol* 2009;55:303-358.
176. Monzo Gardiner JI, Herranz Amo F, Cabello Benavente R, et al. Response to adjuvant chemotherapy after radical cystectomy in patients with infiltrative bladder: analysis of 397 cases. *Arch Esp Urol* 2009;62:275-282.
177. Miller RS, Freiha FS, Torti FM. Surgical Resection of residual tumor mass following chemotherapy for advanced transitional cell carcinoma. *Oncol Muchen Sympomed* 1994;3:370.
178. Boyd SD, Feinberg SM, Skinner DG, et al. Quality of life survey of urinary diversion patients: comparison of ileal conduits versus continent Koch urinary reservoirs. *J Urol* 1987;138:1386-1389.
179. Mansson A, Johnson G, Mansson W. Quality of life after cystectomy: comparison between patients with conduit and those with caecal reservoir urinary diversion. *Br J Urol* 1988;62:240-245.
180. Raleigh ED, Berry M, Monite JE. A comparison of adjustments to urinary diversions: a pilot study. *J Wound Ostomy Continence Nurs* 1995;22:58-63.
181. Bjerre BD, Johansen C, Steven K. Health related quality of life after cystectomy: bladder substitution compared with ileal conduit diversion. A questionnaire survey. *Br J Urol* 1995;75:200-205.
182. Hart S, Skinner EC, Meyerowitz BE, et al. Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit, or cutaneous or urethral Kock pouch. *J Urol* 1999;162:77-81.
183. Porter MP, Penson DF. Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. *J Urol* 2005;173:1318-1322.
184. Somani BK, Gimlin D, Fayers P, et al. Quality of life and body image for bladder cancer patients undergoing radical cystectomy and urinary diversion—a prospective cohort study with systematic review of the literature. *Urology* 2009;74:1138-1143.
185. Mansson A, Al Amin M, Malmstrom PU, et al. Patient-assessed outcomes in Swedish and Egyptian men undergoing radical cystectomy and orthotopic bladder substitution—a prospective comparative study. *Urology* 2007;70:1086-1090.
186. Bartsch G, Daneshmand S, Skinner E, et al. Urinary functional outcomes in female neobladder patients. *World J Urol* 2014;32:221-228.
187. Gerharz EW, Mansson A, Hunt S, et al. Quality of life after cystectomy and urinary diversion: an evidence based analysis. *J Urol* 2006;174:1729-1736.
188. Zietman AL, Sacco D, Skowronski U, et al. Organ-conservation in invasive bladder cancer treated by trans-urethral resection, chemotherapy, and radiation: results of a urodynamic and quality of life study on long-term survivors. *J Urol* 2003;170:1772-1776.
189. Herman JM, Smith DC, Montie J, et al. Prospective quality of life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. *Urology* 2004;64:69-73.
190. Caffo O, Fellin G, Graffer U, et al. Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. *Cancer* 1996;78:1089-1097.
191. Henningsohn L, Wikstrom H, Dickman PW, et al. Distressful symptoms after radical radiotherapy for urinary bladder cancer. *Radiother Oncol* 2002;60:215-225.
192. Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. *J Clin Oncol* 2001;19:4005-4013.
193. Gilbert SM, Dunn RL, Hollenbeck BK, et al. Development and validation of the Bladder Cancer Index: a comprehensive, disease specific measure of health related quality of life in patients with localized bladder cancer. *J Urol* 2010;183:1764-1769.
194. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. *CA Cancer J Clin* 2003;53:5-26.
195. Yagoda A, Watson RC, Gonzalez-Vitale JC, et al. Cis-dichlorodiammineplatinum(II) in advanced bladder cancer. *Cancer Treat Rep* 1976;60:917-923.
196. Saxman SB, Probert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. *J Clin Oncol* 1997;15:2564-2569.
197. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. *J Clin Oncol* 1992;10:1066-1073.
198. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. *Cancer* 1989;64:2448-2458.
199. Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. *J Urol* 1985;133:403-407.
200. Harker WC, Meyers FJ, Freiha FS, et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. *J Clin Oncol* 1985;3:1463-1470.
201. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. *J Clin Oncol* 1990;8:1050-1055.
202. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. *J Clin Oncol* 2000;18:3068-3070.
203. Kaufman D, Raghavan D, Carducci M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. *J Clin Oncol* 2000;18:1921-1927.
204. Moore MJ, Winquist EW, Murray N, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 1999;17:2876-2881.
205. Roberts JT, von der Maase H, Sengelov L, et al. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. *Ann Oncol* 2006;17:v118.
206. Johannsen M, Sachs M, Roigas J, et al. Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer. *Eur Urol* 2005;48:246-251.
207. Vaishampayan UN, Faulkner JR, Small EJ, et al. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. *Cancer* 2005;104:1627-1632.
208. De Santis M, Bellmunt J, Mead C, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II—results of EORTC study 30986. *J Clin Oncol* 2009;27:5634-5639.
209. Dreicer R, Manola J, Roth BJ, et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. *Cancer* 2004;100:1639-1645.
210. Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer unfit for cisplatin-based chemotherapy. *J Clin Oncol* 2011;29:2432-2438.
211. Dreicer R, Manola J, Roth BJ, et al. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. *J Clin Oncol* 2000;18:1058-1061.
212. Sengelov L, Kamy C, Lund B, et al. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. *J Clin Oncol* 1998;16:3392-3397.
213. Dimopoulos MA, Bakoyannis C, Georgoulas V, et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. *Ann Oncol* 1999;10:1385-1388.
214. Garcia del Muro X, Marcuello E, Guma J, et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. *Br J Cancer* 2002;86:326-330.
215. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC 30987/intergroup study. *Proc Am Soc Clin Oncol* 2007;25:1107-1113.
216. Hainsworth JD, Meluch AA, Litchy S, et al. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. *Cancer* 2005;103:2298-2303.
217. Pectasides D, Glotsos J, Bountouroglou N, et al. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. *Ann Oncol* 2002;13:243-250.
218. Meluch AA, Greco FA, Burris HA 3rd, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. *J Clin Oncol* 2001;19:3018-3024.

219. Sternberg CN, Calabro F, Pizzocaro G, et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. *Cancer* 2001;92:2993–2998.
220. Kaufman DS, Carducci MA, Kuzel T, et al. Gemcitabine (G) and paclitaxel (P) every two weeks (GP2w): a completed multicenter phase II trial in locally advanced or metastatic urothelial cancer. *Proc Am Soc Clin Oncol* 2002;21:767a.
221. Dogliotti L, Carteni G, Siena S, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. *Eur Urol* 2007;52:134–141.
222. Michaelson MD, Kaufman DS, Oh WK. Transitional cell carcinoma of the upper uroepithelial tract. *Clin Adv Hematol Oncol* 2003;1:102–104.
223. Gitlitz BJ, Baker C, Chapman Y, et al. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. *Cancer* 2003;98:1863–1869.
224. Hussain M, Vaishampayan U, Du W, et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. *J Clin Oncol* 2001;19:2527–2533.
225. Lin CC, Hsu CH, Huang CY, et al. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma. *J Urol* 2007;177:84–89.
226. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. *Clin Oncol* 2012;30:1107–2213.
227. Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a cisplatin containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. *J Clin Oncol* 2009;27:4454–4461.
228. Bellmunt J, Fougeray R, Rosenberg J, et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. *Ann Oncol* 2013;24:1466–1472.
229. David KA, Mallin K, Milowsky M, et al. Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000. *Cancer* 2009;115:1435–1447.
230. Grabstald H, Whitmore WF, Melamed MR. Renal pelvic tumors. *JAMA* 1971;218:845–854.
231. Lughezzani G, Sun M, Perrotte P, et al. Gender related differences in patients with stage I to III upper tract urothelial carcinoma: results from the SEER database. *Urology* 2010;75:321–327.
232. Walsh IK, Keane PF, Ishak LM, et al. The BTA stat test: a tumor marker for the detection of upper tract transitional cell carcinoma. *Urology* 2001;58:532–535.
233. Skacel M, Fahmy M, Brainard JA, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. *J Urol* 2003;169:2101–2105.
234. Brown CA, Mati SF, Busby JE, et al. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. *Urology* 2007;70:252–256.
235. Lughezzani G, Burger M, Margulis V, et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. *Eur Urol* 2012;62:100–114.
236. O'Malley ME, Hahn PF, Yoder IC, et al. Comparison of excretory phase, helical computed tomography with intravenous urography in patients with painless haematuria. *Clin Radiol* 2003;58:294–300.
237. Jung P, Brauers A, Nolte-Erting CA, et al. Magnetic resonance urography enhanced by gadolinium and diuretics: a comparison with conventional urography in diagnosing the cause of ureteric obstruction. *BJU Int* 2000;86:960–965.
238. Lee KS, Zeikus E, DeWolf WC, et al. MR urography versus retrograde pyelography/ureteroscopy for the exclusion of upper urinary tract malignancy. *Clin Radiol* 2010;65:185–192.
239. Heney NM, Nocks BN. The influence of perinephric fat involvement on survival in patients with renal cell carcinoma extending into the inferior vena cava. *J Urol* 1982;128:18–20.
240. Lughezzani G, Jeldre C, Isbarn H, et al. A critical appraisal of the lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. *Urology* 2010;75:118–124.
241. El Fetouh HA, Rassweiler JJ, Schulze M, et al. Laparoscopic radical nephroureterectomy: results of an international multicenter study. *Eur Urol* 2002;42:447–452.
242. Gill IS, Sung GT, Hobart MG, et al. Laparoscopic radical nephroureterectomy for upper tract transitional cell carcinoma: the Cleveland Clinic experience. *J Urol* 2000;164:1513–1522.
243. Matin SF, Gill IS. Recurrence and survival following laparoscopic radical nephroureterectomy with various forms of bladder cuff control. *J Urol* 2005;173:395–400.
244. Ambani SN, Weizer AZ, Wolf JS Jr, et al. Matched comparison of robotic vs laparoscopic nephroureterectomy: an initial experience. *Urology* 2014;83:345–349.
245. Ong AM, Bhayani SB, Pavlovich CP. Trocar site recurrence after laparoscopic nephroureterectomy. *J Urol* 2003;170:1301.
246. Daneshmand S, Quek ML, Huffman JL. Endoscopic management of upper urinary tract transitional cell carcinoma: long-term experience. *Cancer* 2003;98:55–60.
247. Okubo K, Ichioka K, Terada N, et al. Intrarenal bacillus Calmette-Guerin therapy for carcinoma in situ of the upper urinary tract: long-term follow-up and natural course in cases of failure. *BJU Int* 2001;88:343–347.
248. Cutress ML, Stewart GD, Tudor EC, et al. Endoscopic versus laparoscopic management of noninvasive upper tract urothelial carcinoma: 20-year single center experience. *J Urol* 2013;189:2054–2060.
249. Goel MC, Mahendra V, Roberts JG. Percutaneous management of renal pelvic urothelial tumors: long-term followup. *J Urol* 2003;169:925–929.
250. Thompson RH, Krambeck AE, Lohse CM, et al. Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. *Urology* 2008;71:713–717.
251. Jeldres C, Lughezzani G, Sun M, et al. Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. *J Urol* 2010;183:1324–1329.
252. Colin P, Ouzzane A, Pignot G, et al. Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. *BJU Int* 2012;110:1134–1141.
253. Hall MC, Womack S, Sagalowsky AI, et al. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. *Urology* 1998;52:594–601.
254. Van der Poel HG, Antonini N, Van Tinteren H, et al. Upper urinary tract cancer: location is correlated with prognosis. *Eur Urol* 2005;48:438–444.
255. Isbarn H, Jeldres C, Shariat SF, et al. Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. *J Urol* 2009;182:2177.
256. Holmång S, Johansson SL. Urothelial carcinoma of the upper urinary tract: comparison between the WHO/ISUP 1998 consensus classification and the WHO 1999 classification system. *Urology* 2005;66:274–278.
257. See WA. Continuous antegrade infusion of adriamycin as adjuvant therapy for upper tract urothelial malignancies. *Urology* 2000;56:216–222.
258. Rubenstein MA, Walz BJ, Bucy JC. Transitional cell carcinoma of the kidney: 25 year experience. *J Urol* 1978;119:595–597.
259. Reitelman C, Sawczuk IS, Olsson CA, et al. Prognostic variables in patients with transitional cell carcinoma of the renal pelvis and proximal ureter. *J Urol* 1987;138:1144–1145.
260. Heney NM, Nocks BN, Daly JJ, et al. Prognostic factors in carcinoma of the ureter. *J Urol* 1981;125:632–636.
261. Kirkali Z, Moffat LE, Deane RF, et al. Urothelial tumors of the upper urinary tract. *Br J Urol* 1989;64:18–24.
262. Booth CM, Cameron KM, Pugh RCB. Urothelial carcinoma of the kidney and ureter. *Br J Urol* 1980;52:430–435.
263. Mufti GR, Gove JRW, Badenoch DF, et al. Transitional cell carcinoma of the renal pelvis and ureter. *Br J Urol* 1989;63:135–140.
264. Das AK, Carson CC, Bolick D, et al. Primary carcinoma of the upper urinary tract (effect of primary and secondary therapy on survival). *Cancer* 1990;66:1919–1923.
265. Vahlensieck W Jr, Sommerkamp H. Therapy and prognosis of carcinoma of the renal pelvis. *Eur Urol* 1989;16:286–290.
266. Cozad SC, Smalley SR, Austenfeld M, et al. Transitional cell carcinoma of the renal pelvis or ureter: patterns of failure. *Urology* 1995;46:796–800.
267. Brookland RK, Richter MP. The postoperative irradiation of transitional cell carcinoma of the renal pelvis and ureter. *J Urol* 1985;133:952–955.
268. Ozsahin M, Zouhair A, Villa S, et al. Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre Rare Cancer Network study. *Eur J Cancer* 1999;35:738–743.
269. Maulard-Durdux C, Dufour B, Hennequin C, et al. Postoperative radiation therapy in 26 patients with invasive transitional cell carcinoma of the upper urinary tract: no impact on survival? *J Urol* 1996;155:115–117.
270. Catton CN, Warde P, Gospodarowicz MK, et al. Transitional cell carcinoma of the renal pelvis and ureter: outcome and patterns of relapse in patients treated with postoperative radiation. *Urol Oncol* 1996;2:171–176.
271. Czito B, Zietman AL, Kaufman DS, et al. Adjuvant combined modality therapy in locally advanced upper urinary tract malignancies. *J Urol* 2004;172:1271.
272. Kwak C, Lee SE, Jeong IG, et al. Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. *Urology* 2006;68:53–57.
273. Chen B, Zeng ZC, Wang GM, et al. Radiotherapy may improve overall survival of patients with T3/T4 transitional cell carcinoma of the renal pelvis or ureter and delay bladder tumour relapse. *BMC Cancer*. 2011;11:297.
274. Guinan P, Volgelzang NJ, Randazzo R, et al. Renal pelvic transitional cell carcinoma. The role of the kidney in tumor-node-metastasis staging. *Cancer* 1992;69:1773–1775.
275. Seaman EK, Slawin KM, Benson MC. Treatment options for upper tract transitional-cell carcinoma. *Urol Clin North Am* 1993;20:349–354.

276. Huben RP, Mounzer AM, Murphy GP. Tumor grade and stage as prognostic variables in upper tract urothelial tumors. *Cancer* 1988;62:2016–2120.
277. Charbit L, Gendreau MC, Mee S, et al. Tumors of the upper urinary tract: 10 years of experience. *J Urol* 1991;146:1243–1246.
278. Corrado F, Ferri C, Mannini D, et al. Transitional cell carcinoma of the upper urinary tract: evaluation of prognostic factors by histopathology and flow cytometric analysis. *J Urol* 1991;145:1159–1163.
279. Guinan P, Vogelzang NJ, Randazzo R, et al. Renal pelvic cancer: a review of 611 patients treated in Illinois 1975–1985. Cancer Incidence and End Results Committee. *Urology* 1992;40:393–399.
280. Terrell RB, Cheville JC, See WA, et al. Histopathological features and p53 nuclear protein staining as predictors of survival and tumor recurrence in patients with transitional cell carcinoma of the renal pelvis. *J Urol* 1995;154:1342–1347.
281. Masuda M, Iki M, Takano Y, et al. Prognostic significance of Ki-67 labeling index in urothelial tumors of the renal pelvis and ureter. *J Urol* 1996;155:1877–1881.
282. Rey A, Lara PC, Redondo E, et al. Overexpression of p53 in transitional cell carcinoma of the renal pelvis and ureter. Relation to tumor proliferation and survival. *Cancer* 1997;79:2178–2185.